Our President & CEO, Lynn Seely, M.D., will discuss our recent progress at the H.C. Wainwright 4th Annual BioConnect Investor Conference today at 11:00 a.m. ET, and at the 2026 Stifel Virtual Targeted Oncology Forum tomorrow, May 20, at 4:00 p.m. ET. Watch the webcasts here: http://bit.ly/4dbQ4PX. #Lyell #LBCL #mCRC #celltherapy
Lyell Immunopharma
Biotechnology Research
South San Francisco, CA 21,086 followers
At Lyell, we are advancing next-generation CAR T-cell product candidates for patients with cancer.
About us
Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. We have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. Our culture is based on Science, Respect, Collaboration, and Courage and reflects who we are, the environment we create, and our mission's urgency.
- Website
-
http://www.lyell.com
External link for Lyell Immunopharma
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- South San Francisco, CA
- Type
- Public Company
Locations
-
Primary
Get directions
201 Haskins Way
South San Francisco, CA 94080, US
-
Get directions
500 Fairview Ave N
Suite 560
Seattle, Washington 98109, US
-
Get directions
2525 223rd St SE
Bothell, Washington 98021, US
Employees at Lyell Immunopharma
Updates
-
Thank you Life Science Cares! Lyell appreciates all you do and are here to make a difference in our communities ❤️
April was a powerful month of giving back—thank you to the Lyell Immunopharma team for showing up in so many ways during National Volunteer Month! Throughout the month, Lyell Immunopharma volunteers dedicated their time across the Bay Area—supporting food distribution efforts at Samaritan House of San Mateo County and serving meals at GLIDE. The team also organized a baby supply drive and used those supplies to assemble 36 new parent diaper bags for families served by Ayudando Latinos A Soñar, helping provide essential items for parents during a critical time. Across these efforts, the Lyell Immunopharma team contributed over 140 hours of service—demonstrating a strong commitment to supporting communities across the Bay Area. It’s this kind of consistent, hands-on engagement that creates lasting impact for our nonprofit partners and the communities they serve. Thank you, Lyell Immunopharma, for your continued partnership and commitment to giving back. #LifeScienceCares #LyellImmunopharma #NationalVolunteerMonth #CommunityImpact #TogetherWeCanDoMore
-
Our President & CEO, Lynn Seely, M.D., will discuss our recent progress at the 25th Annual Needham Virtual Healthcare Conference today at 11am ET. Don't miss it! Watch the webcast here: http://bit.ly/3OB0jDN. #Lyell #LBCL #mCRC #celltherapy
-
-
We are excited to welcome Smital Shah to the Lyell Immunopharma Executive Team as Chief Financial and Business Officer. Ms. Shah brings over two decades of extensive leadership experience spanning corporate finance, capital markets and strategic operations. As we enter this transformative chapter of Lyell's growth, her expertise will help drive our efforts to develop next-generation CAR T-cell therapies for cancer patients in need. See our press release here https://lnkd.in/gtNFK_Z2
-
-
Last week, we announced that we have enrolled the first patient in our PiNACLE-H2H Phase 3 clinical trial. PiNACLE-H2H is the first head-to-head trial comparing a next-generation CAR T-cell therapy directly against approved CAR T-cell treatments in aggressive large B-cell lymphoma. As reported by Endpoints News, this study marks an important milestone in CAR T-cell trials, moving beyond single-arm data to direct comparisons that can better inform physicians, patients, and payers. This evidence could meaningfully shape the future standard of care in cell therapy. Learn more at https://lnkd.in/gQ6wn3C9 Or read the Endpoints News article: https://lnkd.in/gM5BivXY
-
We’re pleased to announce the launch of our newly updated website, marking an important milestone in our evolution as a late-stage clinical company with a clear and focused vision for the future of cell therapy. This next chapter shows how we’re building an industry-leading, clinical-stage pipeline of CAR T-cell product candidates designed to be one-time treatments that deliver lasting remissions. The new site provides a clearer view of our progress, our pipeline, and the impact we aim to make for patients with cancer. We invite you to visit the new site to learn more. Visit the website: https://www.lyell.com/
-
-
Today at #ASH2025, we are excited to share new clinical data for ronde-cel demonstrating high rates of durable complete responses and manageable safety appropriate for outpatient administration in patients with large B-cell lymphoma. Ronde-cel is our next generation dual-targeting CD19/CD20 CAR T-cell product candidate in pivotal development . Learn more about the data and our clinical trials here - bit.ly/3Kt9vYV #LBCL #CART #celltherapy
-
-
We are excited to be at #ASH2025 where ronde-cel investigators will be presenting new clinical and translational data. Please stop by these two oral sessions on Sunday!
-